fluid restriction
OtherFluid restriction strategy (fluid target 135 ±5 mL/kg/d)
NCT Number: NCT06954142
The aim of this study is to determine whether restricted fluid intake (135 ±5 mL/kg/day) compared to liberal fluid intake (165 ±5 mL/kg/day) from day 8 of life reduces the incidence of bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age or prior death in preterm infants born <30 weeks gestational age.
Interested in participating?
Request Info8 day and older
All sexes
Interventional
Not applicable
Kantonsspital Aarau AG, Klinik für Kinder u. Jugendliche, Aarau, Switzerland
Complications of preterm birth remain the leading cause of death in children under five years of age worldwide, accounting for approximately one million deaths annually. Among the survivors, bronchopulmonary dysplasia (BPD) is the most common severe complication. BPD is a chronic lung disease characterized by prolonged need for respiratory support and oxygen therapy, poor postnatal growth, and long-term impairments in lung function and neurodevelopment.
Despite advancements in neonatal care, BPD is the most common chronic lung disease in infancy and associated with increased mortality, repeated hospitalisation throughout childhood, impaired lung function up into adulthood, and long-term neurodevelopmental impairment. The incidence of BPD has remained stable over the past 15 years. This is likely due to the improved survival of extremely preterm infants, who are at the highest risk for BPD.
A key feature of evolving BPD is the accumulation of interstitial pulmonary edema, which reduces lung compliance and increases the need for respiratory support, thereby perpetuating a cycle of lung damage.
Currently, diuretics are sometimes used to manage pulmonary edema in preterm infants. While they can improve lung function in the short term, they come with potential risks including bone demineralization, nephrotoxicity, electrolyte imbalances, and impaired growth.
As a potentially safer alternative, fluid restriction is sometimes used to prevent or manage pulmonary edema. It is hypothesized to improve lung mechanics and reduce the need for respiratory support, without the adverse effects associated with medications. However, there is no robust evidence on optimal fluid targets in these patients.
SwissNeoNet, consisting of all nine Swiss NICUs, is a mandatory national registry, where data on all infants born before 32 weeks of gestation and/or with a birth weight < 1501 g are collected. Fluid management practices vary among Swiss neonatal intensive care units (NICUs) following international guidelines recommending 135 to 180 mL/kg/day of fluids. This variation may contribute to the differing rates of BPD and mortality observed across centers, but fluid intake is not routinely captured in SwissNeoNet data, making it difficult to assess its impact.
In summary, although fluid restriction shows potential as a simple and low-risk intervention to reduce the incidence of BPD, current evidence is insufficient to support its routine use. There is a clear need for a robust, contemporary, and pragmatic trial to evaluate whether fluid restriction, started after the first week of life, can safely and effectively reduce the incidence of BPD or death in very preterm infants.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Fluid restriction strategy (fluid target 135 ±5 mL/kg/d)
Liberal fluid intake strategy (fluid target 165 ± 5 mL/kg/d)
Time frame: From enrolment to 36 weeks postmenstrual age
Proportion of infants with BPD measured at 36 weeks postmenstrual age or prior death.
Time frame: From enrolment to 36 weeks postmenstrual age
Major complications of prematurity including necrotising enterocolitis ≥ Bell's stage 2, retinopathy of prematurity requiring treatment, patent ductus arteriosus requiring treatment, abnormal brain ultrasound, late onset sepsis
Time frame: From enrolment to 36 weeks postmenstrual age
Days to reach full feeds defined as 150 ml/kg/d or being off parenteral nutrition
Time frame: From enrolment to 36 weeks postmenstrual age
Treatment with diuretics (days on diuretics)
Time frame: From enrolment to 36 weeks postmenstrual age
Systemic postnatal corticosteroids for prevention or treatment of bronchopulmonary dysplasia
Time frame: At first discharge home, on average 37 weeks postmenstrual age
Duration of mechanical ventilation, non-invasive respiratory support, total positive pressure support, supplemental oxygen support, supplemental home oxygen, home ventilation
Time frame: at birth and 36 weeks postmenstrual age
difference in weight, length, and head circumference z-score at 36 weeks postmenstrual age and at birth, respectively
Time frame: From enrolment to 36 weeks postmenstrual age
Daily caloric intake from day 8 of life to 36 weeks postmenstrual age
Time frame: From enrolment to 36 weeks postmenstrual age
Dehydration (sodium level ≥ 150 mmol/L plus clinical signs of dehydration)
Time frame: From enrolment to 36 weeks postmenstrual age
Fluid overload (sodium level ≤ 130 mmol/L plus clinical signs of fluid overload)
Time frame: At first discharge home, on average 37 weeks postmenstrual age
Postmenstrual age at discharge home
Time frame: At first discharge home, on average 37 weeks postmenstrual age
Tube feeding at discharge home
Time frame: from 36 weeks postmenstrual age, 6-12 and 18-24 months post-term
Growth (weight, length, and head circumference z-score)
Time frame: from 36 weeks postmenstrual age, 6-12 and 18-24 months post-term
Respiratory outcome as per Basel-Bern-Infant-Lung-Development cohort study questionnaire
Time frame: From discharge to 6-12 and 18-24 months
Visits to the emergency department from discharge to 6-12 months for any reason
Time frame: from enrolment to 18-24 months post-term
Neurodevelopmental outcome as per PARCA-R questionnaire
Interested in participating?
Request InfoUniversity Children's Hospital Basel
Other
Restricted Versus Liberal Fluid Intake for Prevention of Bronchopulmonary Dysplasia - RELIEF Trial. A Cluster-randomised Multiple Period Cross-over Trial.
Acronym: RELIEF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07307612
Bronchopulmonary Dysplasia, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT06589245
Bronchopulmonary Dysplasia, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Kansas City, Missouri, United States
View Trial DetailsNCT06373289
Bronchopulmonary Dysplasia, Cardiovascular Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06915441
Bronchopulmonary Dysplasia, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Houston, Texas, United States
View Trial Details